Menu Search

Company Announcements

Biodexa Pharmaceuticals PLC

Exercise of Warrants and Issue of Equity

Source: RNS
RNS Number : 0575F
Midatech Pharma PLC
17 March 2022
 

17 March 2022

 

Midatech Pharma PLC

("Midatech" or the "Company")

Exercise of Warrants and Issue of Equity

Total Voting Rights

Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it has received a notice of exercise of warrants over 26 ordinary shares of 0.1p each in the Company ("Ordinary Shares") at an exercise price of £10.00 per share.

Application will be made for the admission of the 26 new Ordinary Shares to trading on the AIM Market of the London Stock Exchange plc ("Admission"), which is expected to become effective at 8.00 a.m. on or around 22 March 2022. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. 

The Company's issued share capital following Admission will comprise 98,468,413 Ordinary Shares each with voting rights. The Company does not hold any shares in treasury. This figure of 98,468,413 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

For more information, please contact:

Midatech Pharma PLC

 

Stephen Stamp, CEO, CFO

 

Tel: +44 (0)29 2048 0180

 

www.midatechpharma.com

 

 

 

Strand Hanson Limited (Nominated and Financial Adviser)

 

James Dance / Matthew Chandler / Rob Patrick

 

Tel: +44 (0)20 7409 3494

 

 

 

Turner Pope Investments (TPI) Limited (Broker)

 

Andrew Thacker / James Pope (Corporate Broking)

Tel: +44(0)20 3657 0050

 

 

 

IFC Advisory Limited (Financial PR and UK Investor Relations)

 

Tim Metcalfe / Graham Herring

 

Tel: +44 (0)20 3934 6630

 

Email: midatech@investor-focus.co.uk

 

 

 

Edison Group (US Investor Relations)

Alyssa Factor

Tel: +1 (860) 573 9637

Email: afactor@edisongroup.com

 

 

 

About Midatech Pharma PLC

Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The Company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.

 

The Company has developed three in-house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform:

 

·    Q-Sphera™ platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months).

·    MidaSolve™ platform: an innovative nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours.

·    MidaCore™ platform: a leading-edge nanotechnology used for targeting medications to sites of disease.

 

The platform nature of the technologies offers the potential to develop multiple drug assets rather than being reliant on a limited number of programmes. Midatech's technologies are supported by 36 patent families including 120 granted patents and an additional 70 patent applications. Midatech's headquarters and R&D facility is in Cardiff, UK. For more information, please visit www.midatechpharma.com

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEEAFDKFFSAEAA